Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Cablivi is the first nanobody-based medicine from the French pharma’s pipeline to receive regulatory approval. The drug will be a part of Sanofi Genzyme’s Rare Blood Disorders franchise ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

“The Gaucher Initiative has empowered the diagnosis and management of this rare disease in Egypt, aiming that no patient is left behind.” Beyond Gaucher disease, Sanofi's Rare Humanitarian ...